性别肯定激素治疗对精子发生的影响:睾丸组织学标本分析
回顾性单中心队列研究纳入2017年11月至2024年1月接受性别肯定睾丸切除术的287例TGD患者、573份睾丸标本。与未使用抗雄激素相比,环丙孕酮和孕酮显著损害精子发生,而螺内酯不显著。环丙孕酮组活动性精子发生仅8.7%,螺内酯组为53.3%(P<0.001)。
要点
- 环丙孕酮组活动性精子发生8.7%,低于螺内酯组的53.3%(P<0.001)。
- 孕酮使用对精子发生有独立负面影响(P=0.005)。
- 年龄较大与精子发生受损相关,终末期睾丸衰竭者平均年龄41.4岁。
核心结论
- 与未使用抗雄激素相比,环丙孕酮和孕酮显著损害精子发生,而螺内酯不显著。
- 这些发现为TGD个体的生育咨询提供临床相关见解,可能有助于基于生殖目标个体化选择激素方案。
研究设计与样本
- 回顾性单中心队列研究,纳入2017年11月至2024年1月接受性别肯定睾丸切除术的287例TGD患者。
- 共组织学审阅573份睾丸标本;所有患者术前均接受性别肯定激素治疗,暴露按激素治疗类型和持续时间分类。
- 主要暴露变量为雌激素使用(N=287,100%)、抗雄激素类型(环丙孕酮:N=127,44.3%;螺内酯:N=110,38.3%)和孕酮使用(N=73,25.4%)。
主要发现
- 手术时平均年龄33.9岁(SD=11.7,范围18.4-80.6),性别肯定激素治疗持续时间3.8年(SD=3.0,范围1-28)。
- 终末期睾丸衰竭者平均年龄41.4岁(SD=12.8,范围23.0-66.5),完全成熟者平均年龄33.4岁(SD=11.2,范围20.2-80.6),差异P=0.002。
- 激素治疗持续时间在组间无显著差异(P=0.22)。
- 环丙孕酮组仅8.7%患者有活动性精子发生,螺内酯组为53.3%(P<0.001)。
- 孕酮使用对精子发生有独立负面影响(P=0.005)。
临床怎么用
- 作者认为这些发现为TGD个体的生育咨询提供临床相关见解,强调环丙孕酮和孕酮显著损害精子发生,而螺内酯可能允许更大程度保留精子成熟。
- 作者认为这对性别肯定激素治疗开始前的生育力保存讨论有启示,并可能有助于基于生殖目标个体化选择激素方案。
局限性
- 回顾性设计及缺乏未治疗个体对照组限制直接因果推断。
- 性别肯定激素治疗持续时间、依从性和方案组成的变异性可能因自我报告引入混杂效应。
- 仅组织学评估不能确认功能性生育潜力,未来研究应探索此方面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How does gender-affirming hormone therapy (GAHT) regimen impact testicular spermatogenesis in transgender and gender diverse (TGD) individuals? SUMMARY ANSWER: Cyproterone acetate (CPA) and progesterone significantly impair spermatogenesis, whereas spironolactone does not, compared to no use of anti-androgen. WHAT IS KNOWN ALREADY: GAHT is known to suppress spermatogenesis in TGD individuals assigned male at birth, but the extent of impairment varies across hormone regimens. Prior studies suggest that anti-androgens and progestogens may exert distinct effects on testicular function, but direct comparisons between regimens are limited. STUDY DESIGN, SIZE, DURATION: This was a retrospective single-center cohort study including 287 TGD patients who underwent gender-affirming orchiectomy between November 2017 and January 2024. A total of 573 testis specimens were histologically reviewed. PARTICIPANTS/MATERIALS, SETTING, METHODS: All included patients had received GAHT prior to surgery, with exposure categorized based on the type and duration of hormone therapy. The primary exposure variables were estrogen use (N = 287, 100%), anti-androgen type (CPA: N = 127, 44.3%; spironolactone: N = 110, 38.3%), and progesterone use (N = 73, 25.4%). Testicular histology was evaluated to determine spermatogenesis stage, and multivariable regression was performed to identify independent predictors of impaired sperm maturation. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 287 patients were included in the study period, and 573 testis specimens were reviewed. Mean age at surgery was 33.9 years (SD = 11.7, range = 18.4-80.6), and duration of GAHT was 3.8 years (SD = 3.0, range = 1-28). Older age was associated with impairment in spermatogenesis, with a mean age of 41.4 (SD = 12.8, range = 23.0-66.5) for end-stage testis failure and a mean age of 33.4 (SD = 11.2, range = 20.2-80.6) for complete maturation (P = 0.002). Hormone therapy duration did not show a significant difference between groups (P = 0.22). GAHT included estrogen (n = 287, 100%), progesterone (n = 73, 25.4%), and an anti-androgen (n = 259, 90.2%). CPA (n = 127, 44.3%) and spironolactone (N = 110, 38.3%) were the most common anti-androgens used. Spermatogenesis was most significantly impaired with the use of CPA, with only 8.7% of patients having active spermatogenesis versus 53.3% of patients taking spironolactone (P < 0.001). Progesterone use had an independent negative effect on spermatogenesis (P = 0.005). LIMITATIONS, REASONS FOR CAUTION: The retrospective design and absence of a control group of untreated individuals limit direct causal inferences. Variability in GAHT duration, adherence, and regimen composition may introduce confounding effects due to self-reporting. Additionally, histological assessment alone does not confirm functional fertility potential, and future studies should explore this aspect. WIDER IMPLICATIONS OF THE FINDINGS: These findings provide clinically relevant insights for fertility counseling in TGD individuals, emphasizing that CPA and progesterone significantly impair spermatogenesis, whereas spironolactone may allow for greater preservation of sperm maturation. This has implications for fertility preservation discussions prior to GAHT initiation and may inform individualized hormone regimen selection based on reproductive goals. STUDY FUNDING/COMPETING INTEREST(S): This research received no specific grant or funding. The authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: n/a.
引用
- Wilk Goldsher Y, Al-Hadi H, Mullen B, et al. Impact of gender-affirming hormone therapy on spermatogenesis: analysis of testicular histological specimens. Hum Reprod. 2026. PMID: 41206903. doi:10.1093/humrep/deaf216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。